WO2017198199A1 - Chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire, son procédé de préparation et ses applications - Google Patents

Chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire, son procédé de préparation et ses applications Download PDF

Info

Publication number
WO2017198199A1
WO2017198199A1 PCT/CN2017/084944 CN2017084944W WO2017198199A1 WO 2017198199 A1 WO2017198199 A1 WO 2017198199A1 CN 2017084944 W CN2017084944 W CN 2017084944W WO 2017198199 A1 WO2017198199 A1 WO 2017198199A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorus
iron
low molecular
molecular weight
composition
Prior art date
Application number
PCT/CN2017/084944
Other languages
English (en)
Chinese (zh)
Inventor
王伟
许婧
陆佳美
包丽霞
贺利军
仇波
肖飞
Original Assignee
欣凯医药化工中间体（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 欣凯医药化工中间体（上海）有限公司 filed Critical 欣凯医药化工中间体（上海）有限公司
Publication of WO2017198199A1 publication Critical patent/WO2017198199A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a phosphorus binder, and in particular to an iron salt-low molecular weight sugar-based phosphorus binder, a preparation method thereof and use thereof.
  • Hyperphosphatemia is one of the major complications of chronic renal insufficiency (CKD). Increased serum phosphorus concentration is closely related to mortality in CKD patients, and elevated blood phosphorus levels may lead to further decline in renal function and secondary thyroid function. , vascular calcification and minerals, bone metabolism disorders. It is widely believed that regulating phosphorus metabolism is the key to reducing cardiovascular complications, improving the quality of life of dialysis patients, and reducing morbidity and mortality.
  • CKD chronic renal insufficiency
  • the iron-phosphorus binder has been proven to be a high-efficiency phosphorus binder and does not cause ectopic calcification and can improve thyroid function. At the same time, it helps to correct the anemia of CKD patients and has no significant effect on iron metabolism in the body.
  • a first aspect of the invention provides a phosphorus binder comprising:
  • the number of monosaccharide units of the low molecular weight sugar is from 1 to 20, and the mass ratio of iron is from 2 to 45% by weight based on the total weight of the phosphorus binder.
  • the low molecular weight sugar has a monosaccharide unit number of from 1 to 10, preferably from 3 to 9, more preferably from 4 to 7.
  • the low molecular weight sugar has a number of monosaccharide units of from 3 to 20.
  • the mass ratio of iron is from 10 to 35 wt%, preferably from 25 to 33 wt%, based on the total weight of the phosphorus binder.
  • the low molecular weight sugar comprises a monosaccharide, an oligosaccharide, and/or a polysaccharide.
  • the low molecular weight sugar comprises a monosaccharide and an oligosaccharide.
  • the monosaccharide is selected from the group consisting of fructose, arabinose, glucuronic acid, glucose, galactose, or a combination thereof.
  • the polysaccharide is selected from the group consisting of gum arabic, peach gum, guar gum, konjac gum, carrageenan, sodium alginate, pectin, dextran, or a combination thereof.
  • the hydroxide of iron forms a stable structure with the low molecular weight sugar by hydrogen bonding or adsorption (coordination).
  • the phosphorus binder has a citrate content of from 1 to 30%, preferably from 3 to 15%, more preferably from 5 to 11%.
  • a second aspect of the invention provides the use of the phosphorus binder of the first aspect of the invention for the preparation of a composition for inhibiting an increase in blood phosphorus concentration.
  • the composition is also used to (i) enhance immunity; and/or (ii) treat or prevent hyperphosphatemia, hyperparathyroidism, calcium-phosphorus product change, vitamin D metabolism Disorders, renal osteopathy, and diseases associated with cardiovascular complications.
  • composition is also used to supplement iron.
  • the composition comprises a pharmaceutical composition, a health care composition, a food composition, or a combination thereof.
  • the composition comprises a safe and effective amount of (i) a hydroxide of iron; (ii) a low molecular weight sugar;
  • the composition is an oral preparation.
  • the composition is a preparation selected from the group consisting of a terminal preparation, a powder, a tablet, a sugar coating agent, a capsule, a granule, a suspension, a solution, a syrup, a drop, and a tongue. Under the tablet.
  • the composition contains a therapeutically effective amount of an iron salt, a carbohydrate, and an additive selected from the group consisting of flavoring agents, preservatives, dispersing agents, coloring agents, perfumes, capsule shells, and helpers.
  • an additive selected from the group consisting of flavoring agents, preservatives, dispersing agents, coloring agents, perfumes, capsule shells, and helpers.
  • a third aspect of the invention provides a method for preparing a phosphorus binder according to the first aspect of the invention, comprising the steps of:
  • the weak base is sodium citrate, potassium citrate, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, or a mixture thereof.
  • the weak base is citric acid, sodium citrate, and/or sodium citrate hydrate.
  • the sodium citrate hydrate comprises trisodium citrate dihydrate.
  • the weak base comprises sodium citrate.
  • the mass ratio of the low molecular weight sugar to the weak base is 1:0.01-1, preferably 1:0.1-0.5, more preferably,1. : 0.2-0.3.
  • the mass ratio of the low molecular weight sugar to the iron hydroxide is 1:0.2-4, preferably 1:0.5-1, more preferably Ground, 1:0.6-0.7.
  • the step (b1) is included: mixing the low molecular weight sugar of the step (a), sodium citrate and a base in water, adding an iron salt and a base to obtain a product, and separating and purifying The phosphorus binder of the first aspect of the invention is obtained.
  • said step (b1) has one or more of the following features:
  • reaction time is 1-48 h, preferably 1-24 h, more preferably 4-16 h;
  • the cooling temperature is 0-40 ° C;
  • step (b1) purification is carried out with ethanol.
  • the ethanol contains 5-20% water.
  • the ethanol is anhydrous ethanol or 90-95% ethanol.
  • the ethanol and water (v/v) are from 1:0.05 to 1:10.
  • step (b1) further comprises a stirring and cooling step.
  • the iron salt is selected from the group consisting of a divalent iron salt, a ferric salt, or a combination thereof.
  • the iron salt is a ferric salt selected from the group consisting of ferric chloride, iron nitrate, iron sulfate, iron citrate, or a combination thereof.
  • the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, aqueous ammonia, or a combination thereof.
  • the method further comprises the step (c) of separating the product by drying to obtain the phosphorus binder in the form of a dry powder.
  • the drying comprises product drying, heat drying, spray drying or fluidized spray drying.
  • a fourth aspect of the invention provides a composition comprising: the phosphorus binder of the first aspect of the invention.
  • a pharmaceutically acceptable carrier is selected from:
  • the composition is an oral preparation.
  • the composition is a preparation selected from the group consisting of a terminal preparation, a powder, a tablet, a sugar coating agent, a capsule, a granule, a suspension, a solution, a syrup, a drop, and a tongue. Under the tablet.
  • the composition contains a therapeutically effective amount of an iron salt, a carbohydrate, and an additive selected from the group consisting of flavoring agents, preservatives, dispersing agents, coloring agents, perfumes, capsule shells, and helpers.
  • an additive selected from the group consisting of flavoring agents, preservatives, dispersing agents, coloring agents, perfumes, capsule shells, and helpers.
  • the composition contains from 0.1 to 99% by weight, preferably from 10 to 90% by weight, of the phosphorus binder, based on the total weight of the composition.
  • the composition is a unit dosage form (one tablet, one capsule or one vial), and the mass of the composition in each unit dosage form is from 0.05 to 5 g, preferably from 0.5 to 2 g.
  • the subject comprises a human or a non-human mammal.
  • the non-human mammal comprises a rodent such as a mouse or a rat.
  • the iron hydroxide of the present invention is not particularly limited, and a preferred iron hydroxide is iron hydroxide, iron oxyhydroxide, and iron oxide.
  • each of the low molecular weight sugars comprises on average 1 to 20 (preferably, 1 to 10, more preferably, 3 to 9, more preferably 4 to 7) monosaccharide units or each of the above
  • the low molecular weight sugars on average comprise from 3 to 20 (preferably, 3 to 10, more preferably, 4 to 9, more preferably 4 to 7) monosaccharide units, usually of small molecular weight (ie, monosaccharide singles)
  • the number of elements may be reduced by pretreatment (for example, using an acid and/or heat or an enzyme such as an alpha-amylase), and the low molecular weight sugar may be a linear chain of monosaccharide units linked by a (1 ⁇ 4) glycosidic bond; Or it may be branched by forming a (1 ⁇ 6) glycosidic bond.
  • a preferred method of preparing a phosphorus binder includes the following steps:
  • a phosphorus binder 0.1-90 wt% of a phosphorus binder; and a food or pharmaceutically acceptable carrier, and/or an excipient.
  • the phosphorus binder-containing composition of the present invention has remarkably excellent phosphorus binding ability, and thus can be used for treating and/or preventing hyperphosphatemia in a mammal.
  • the mammal of the present invention may be referred to as a human, and may also be a warm-blooded animal, especially a cat, a dog or the like.
  • the test method for the absorption capacity of phosphoric acid was as follows: a phosphoric acid solution having a concentration of 2 ⁇ g/mL was prepared, and the pH was adjusted to 3.0 with sodium hydroxide hydrochloride, and the sample was designated as Control A. Add 25 mL of Control A to the prepared phosphorus binder 100 ⁇ 5 mg (denoted as B), and react at 37 ° C for 24 h with low speed stirring. After 24 hours, the reaction solution was centrifuged (14,000 rpm), and the supernatant was taken at a concentration of C. The concentrations of A and C were determined using an ultraviolet spectrophotometer, respectively. The phosphate binding capacity is calculated by the formula:
  • Adsorption activity (mg/g) is defined as the mass of phosphate (PO 4 3- ) adsorbed per gram of API
  • the iron content was found to be 32.4%, and the phosphorus absorption was 342.1 mg/g.
  • Ethanol was completely precipitated and centrifuged, and the solid was washed twice with 70% ethanol and 80% ethanol respectively.
  • the obtained product was heated and dried to obtain 372.4 g of product.
  • the product was dark brown and the particle size was 11.2 nm. Dissolved in water.
  • the iron content was found to be 31.2%, and the phosphorus absorption was 195.6 mg/g.
  • the iron content was found to be 32.4%, and the phosphorus absorption was 284.3 mg/g.
  • the mixture was centrifuged, and the solid was washed twice with 70% ethanol and 80% ethanol respectively; the obtained product was dried by heating, and a total of 363 g of the product was obtained.
  • the product was reddish brown with a particle size of 14.2 nm and was easily soluble in water.
  • the experimental animals were fed freely without human intervention and continued for 2 weeks.
  • the following indicators were observed and tested: animal survival (during the experiment), 24-hour food intake, body weight (once a week), blood phosphorus, blood calcium, iron, creatinine, BUN (1 day before administration, 2nd after administration) Week), urine volume (24 hours), urinary iron, urinary phosphorus (1 day before administration, 2 weeks after administration).
  • the phosphorus-binding agent of the present invention has a significantly lower blood phosphorus-lowering effect than the positive drug, and has a very significant hypophosphatemic effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire. Le nombre d'unités monosaccharidiques dans les sucres de faible poids moléculaire varie de 1 à 20. Sur la base du poids total du chélateur des phosphates, le rapport massique du fer varie de 2 % en poids à 45 % en poids. Le chélateur des phosphates est utilisé pour réduire la concentration des phosphates sériques.
PCT/CN2017/084944 2016-05-19 2017-05-18 Chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire, son procédé de préparation et ses applications WO2017198199A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610341394.6A CN107397760B (zh) 2016-05-19 2016-05-19 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用
CN201610341394.6 2016-05-19

Publications (1)

Publication Number Publication Date
WO2017198199A1 true WO2017198199A1 (fr) 2017-11-23

Family

ID=60325738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/084944 WO2017198199A1 (fr) 2016-05-19 2017-05-18 Chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire, son procédé de préparation et ses applications

Country Status (2)

Country Link
CN (1) CN107397760B (fr)
WO (1) WO2017198199A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317494A (zh) * 2022-07-22 2022-11-11 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970989B (zh) * 2019-04-23 2021-07-06 北京市中关村医院 一种MOFs结构的磷结合剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997596A (zh) * 2004-06-28 2007-07-11 维福（国际）股份公司 基于硫酸铁的磷酸盐吸附剂
CN101563295A (zh) * 2006-12-14 2009-10-21 诺瓦提斯公司 基于铁(ⅲ)-碳水化合物的磷酸盐吸附剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523897A (ja) * 2008-06-13 2011-08-25 ノバルティス アーゲー 鉄を含有するリン酸塩吸着剤を調製するための製造プロセス
MX2011009144A (es) * 2009-03-02 2011-09-15 Vifor Int Ag Adsorbente de fosfato.
US20110269837A1 (en) * 2010-05-03 2011-11-03 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
JP6189309B2 (ja) * 2011-10-13 2017-08-30 ヴィダシム・インコーポレーテッド 鉄−繊維組成物、その調製および使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997596A (zh) * 2004-06-28 2007-07-11 维福（国际）股份公司 基于硫酸铁的磷酸盐吸附剂
CN101563295A (zh) * 2006-12-14 2009-10-21 诺瓦提斯公司 基于铁(ⅲ)-碳水化合物的磷酸盐吸附剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317494A (zh) * 2022-07-22 2022-11-11 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法
CN115317494B (zh) * 2022-07-22 2024-02-13 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法

Also Published As

Publication number Publication date
CN107397760A (zh) 2017-11-28
CN107397760B (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
TWI465239B (zh) 多核的鐵（III）為基礎之磷酸鹽吸附劑，包含其之組合物及固體或半固體劑型，其製備方法及用途，及製備γ-氧化鐵（III）-氫氧化物之方法
KR101951857B1 (ko) 마그헤마이트 또는 마그헤마이트/마그네타이트에 기초한 나노미립자 인산염 흡착제, 이의 제법 및 용도
ES2732290T3 (es) Compuestos de complejo de hierro-hidrato de carbono
DK2319804T3 (en) Iron (III) -carbohydrat-based phosphatadsorbens
EP2983527B1 (fr) Compositions complexes à constituant ion métallique-fibre fonctionnelle, leur préparation et leurs utilisations
JP2002508772A (ja) 健康補助剤
CA2825594C (fr) Compositions nutritives hydrosolubles comprenant du beta-glucane de cereale et de l'amidon resistant
KR20110018434A (ko) 철 함유 인산염 흡착제의 제조를 위한 제조 방법
JP2005068060A (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
JP5757493B1 (ja) 経口型鉄分補給用固形組成物及びその製造方法
JP2009517359A (ja) 三価鉄錯体およびレドックス活性物質を含有する薬剤
KR20110128329A (ko) 인산염 흡착제
WO2017198199A1 (fr) Chélateur des phosphates comprenant de l'hydroxyde de fer et des sucres de faible poids moléculaire, son procédé de préparation et ses applications
EP3755343A1 (fr) Nouveau procédé de préparation de composition de glycane et ses utilisations
CN105193844A (zh) 用于制备含δ-羟基氧化铁(多核)及其药物组合物的方法及在高磷血症领域中的应用
CN107397810B (zh) 基于铁的氢氧化物－桃胶的磷结合剂、其制备方法及其应用
EP3530281A1 (fr) Nouveau procédé de préparation de compositions de glycane et leurs utilisations
CN107397758A (zh) 一种磷结合剂及其制备方法
JP6307710B2 (ja) 新規使用
JP2004051615A (ja) キトサン・オロチン酸塩を使用する胆汁酸吸着剤。
JP4721684B2 (ja) ダイフラクトースアンハイドライド含有経口組成物
CN107397759A (zh) 基于铁的氢氧化物－降解的碳水化合物的磷结合剂、其制备方法及其应用
WO2018189649A1 (fr) Compositions orales pour le traitement de troubles de carence en fer
JP2020040900A (ja) 腎臓病の進行抑制剤、予防剤、および治療剤
KR20220155132A (ko) 캡슐화된, 코디세핀이 삽입된 하이드로탈사이트를 포함하는 약물의 선택적 전달을 위한 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17798762

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 07/03/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17798762

Country of ref document: EP

Kind code of ref document: A1